Literature DB >> 27530310

A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients.

Athena Alipour-Faz1, Maziar Shojaei2, Hassan Peyvandi3, Davood Ramzi1, Mahbobeh Oroei4, Fereshteh Ghadiri2, Maryam Peyvandi1.   

Abstract

Myasthenia gravis (MG) is one of the curable neurologic disorders. Various pharmacological therapies are administered for these patients and a thymectomy plays an important role in the therapy of myasthenia gravis, which develops a permanent or relative remission. We investigated the efficacy of intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) as a preparation before thymectomy in patients with MG. This randomized clinical trial was conducted on 24 patients with MG referred for thymectomy, which were randomized to two groups of IVIG and PLEX. The IVIG group received IVIG 1 g/kg/day for two consecutive days and the PLEX group underwent 1-L plasma exchange five times with 5 % albumin replacement fluid, every other day, 10-30 days before the procedure. The duration of hospitalization (day), length of intensive care unit (ICU) stay after surgery (day), length of intubation period (h), duration of surgery (h) and dose of steroid administered were compared between the two groups. Analysis was performed via SPSS version 20. In the PLEX group, post-operative outcomes (duration of hospitalization, ICU length of stay after surgery, intubation period and duration of surgery) were longer than those in the IVIG group. There was significant difference in intubation period (p value = 0.01) and duration of surgery (p value = 0.05) between the PLEX and IVIG groups. The administration of IVIG in comparison to PLEX can be more effective in the preparation before thymectomy in myasthenia gravis patients.

Entities:  

Keywords:  Intravenous immunoglobulin; Myasthenia gravis; Plasma exchange; Thymectomy

Mesh:

Substances:

Year:  2016        PMID: 27530310     DOI: 10.1007/s13760-016-0689-z

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  5 in total

Review 1.  Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Authors:  Deepak Menon; Vera Bril
Journal:  Drugs       Date:  2022-05-31       Impact factor: 11.431

Review 2.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

3.  Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.

Authors:  Josep Gamez; María Salvadó; Francesc Carmona; Miriam de Nadal; Laura Romero; Daniel Ruiz; Alberto Jáuregui; Olga Martínez; Javier Pérez; Pilar Suñé; María Deu
Journal:  Ther Adv Neurol Disord       Date:  2019-07-17       Impact factor: 6.570

4.  Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis.

Authors:  Chaoying Liu; Peng Liu; Mei Ma; Hongxia Yang; Guoyan Qi
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

5.  Myasthenic crisis and late deep vein thrombosis following thymectomy in a patient with myasthenia gravis: A case report.

Authors:  Cheng-Yuan Lin; Wei-Cheng Liu; Min-Hsien Chiang; I-Ting Tsai; Jen-Yin Chen; Wan-Jung Cheng; Chun-Ning Ho; Shu-Wei Liao; Chin-Chen Chu; Cheuk-Kwan Sun; Kuo-Chuan Hung
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.